目的评价双歧杆菌三联活菌制剂治疗功能性便秘的临床疗效。方法检索中国知网、万方、维普、Pubmed、EMbase、Webof Science数据库，收集2005年1月至2013年12月国内外应用双歧杆菌三联活菌制剂治疗功能性便秘的所有随机对照试验（randomized controlled trial，RCT）和前瞻性非随机对照试验（non—randomized controlled trial，non-RCT）。按照纳入与排除标准选择文献、提取资料和评价纳入研究的方法学质量后，采用Cochrane协作网提供的RevMan5．2软件进行Meta分析。结果无RCT入选，纳入18个前瞻性non-RCT，共1397例患者。治疗组（对照组常规治疗措施＋双歧杆菌三联活菌胶囊或散剂）718例，对照组679例。治疗组的总体疗效优于对照组（OR3．98，95％CI：2．46～6．43，P〈0．01）；治疗组功能性便秘复发率低于对照组（OR0．23，95％CI：0．14～036，P〈0．01）；治疗组不良反应发生率与对照组比较，差异无统计学意义（OR0．70，95％CI：0．37～134，P=0．29）。结论双歧杆菌三联活菌制剂与常规治疗药物联用可以提高功能性便秘的总体疗效，同时可以有效降低功能性便秘的复发率。
Objective To evaluate the clinical therapeutic effect of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules/powder in treating functional constipation by Meta-analysis. Methods Such databases as China Knowledge Resource Integrated Database, Wanfang Database, Vip Database, Pubmed, Embase and Web of Science were searched from establishing database to december 2015 to collect all Randomized controlled trials （RCTs） and prospective Non-randomized controlled trials （non-RCTs） on live combined Bifidobacterium, Lactobacillus and Enterococcus capsules/powder in treating functional constipation. The included time of all studies ranges from January 2005 to December 2013 and the studies were selected according to the inclusion and exclusion criteria. The data were extracted, the methodological quality of the included studies was assessed, and the Meta-analysis was performed with RevmanS.2. Results A total of 18 prospective non-RCTs involving 1397 patients were included, including 718 patients from treatment group （live combined Bifidobacterium, Lactobacillus and Enterococcus capsules/powder plus conventional treatment） and 679 patients from control group （conventional treatment）. The total effective rate of the treatment group was superior to that of the control group （OR 3.98, 95%CI 2.46-6.43, P〈0.01）; the recurernce rate of the treatment group was lower than that of the control group （OR 0.23, 95%CI 0.14-0.36, P〈0.01）; there was no statistical significance between two groups in incidence of adverse reaction （OR 0.70, 95%CI 0.37-1.34, P=0.29）. Conclusion Live combined Bifidobacterium, Lactobacillus and Enterococcus capsules~powder combined with conventional drugs can improve the total therapeutic effect of functional constipation, reduce the recurernce rate of functional constipation.
Chinese Journal of Practical Internal Medicine
live combined Bifidobacterium, Lactobacillus and Enterococcus capsules/powder